

Welke medicamenteuze behandelingen zijn er en wat komt eraan?

IBD-patiëntendag 11 maart 2023

Dr. W.A. van Dop, MDL-arts



'Oudere' medicatie:



- Entocort/cortiment,
- prednison
- Mesalazine
- Thiopurines
- Methotrexaat

'Nieuwere' medicatie

- anti-TNF
(infliximab, adalimumab, golimumab)
- Anti-IL12/IL23
(ustekinumab)
- Integrineremmer
(vedolizumab)
- Jak-remmers
(tofacitinib, fligotinib, upadacitinib)
- S1P-modulatoren
(ozanimod)


Toekomstige medicatie ?


- anti-TNF
(-)
- Anti-IL23
(mirikizumab, guselkumab, brazikumab, risankizumab)
- Integrineremmer
(etrolizumab)
- Jak-remmer
(Crohn: **upadacitinib**)
- S1P-modulatoren
(etrazimod)



bacterieën


D A R M









bacterieën

D A R M






lymfeklier




bacterieën


D A R M








D A R M

















bacterieën

D A R M

Gezonde darm



Ontstoken darm



bacterieën

D A R M

Anti-TNF


- Infliximab
- Adalimumab
- golimumab


Anti-IL23

- Ustekinumab - remt echter ook IL12!!


In onderzoeksfase, specifieke IL23-remmers:

- Mirikizumab
- Risankizumab
- Guselkumab
- brazikumab







bloedvat




Integrineremmers

- vedolizumab
- etrolizumab




bacterieën

D A R M



JAK-remmers


- Tofacitinib → JAK1,2,3
- Filgotinib → JAK1
- upadacitinib → JAK1



Conclusie/samenvatting


Anti-TNF

Infliximab
Adalimumab
golimumab



S1P-remmers

Ozanimod
Etrasimod




JAK-remmers

Tofacitinib
Filgotinib
Upadacitinib




Anti-IL23

Ustekinumab
Mirikizumab
Guselkumab
Risankizumab
brazikumab



Integrine-remmers

Vedolizumab
Etrolizumab



Colitis

IFX
Adalimumab
Golimumab
Vedolizumab
Ustekinumab
Tofacitinib
Filgotinib
Upadacitinib
Ozanimod

Crohn

IFX
Adalimumab
Vedolizumab
Ustekinumab

Later 2023:
Upadacitinib
Risankizumab

Biosimilars

Infliximab

Eerst alleen remicade

Nu: flixabi, inflectra, remsima, zessly

Adalimuab

Eerst alleen humira

Nu: hyrimoz, imraldi, amgevita, hukyndra, idacio, yuflyma

Switchen naar biosimilar is effectief en veilig! (en vele malen goedkoper)

Echter: igv hyrimoz: citraat als hulpstof → soms pijnlijke injecties



The image shows a screenshot of a news article from nrc.nl. The article title is "Stichting dagvaardt AbbVie om 'excessieve' winst met reumamedicijn Humira". The sub-headline reads: "Farmaceut Farma ter Verantwoording dagvaardt Abbvie in een civiele procedure. Het zet voor het veelgebruikte reumamedicijn Humira 1,2 miljard euro te veel hebben gerekend." The article is dated 21 februari 2023 and is 3 minutes long. Below the text is a photograph of a white box of HUMIRA adalimumab 40 mg/0.4 mL syringes, with a red circular sticker on the box indicating the dosage.

Steeds meer middelen ook s.c. optie:

IFX s.c. elke 2 weken




Vedolizumab s.c. elke 2 weken



Uitdagingen voor in de toekomst:

- Wat werkt bij wie? - 'personalized medicine'
- Volgorde?
- Onderling vergelijk?
- Combinaties mogelijk?
- Wanneer stoppen/afbouwen?



V R A G E N ?

